Update Alert 4: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
作者信息
Mackey Katherine, Kansagara Devan, Vela Kathryn
机构信息
VA Portland Health Care System, Portland, Oregon (K.M., D.K., K.V.).
出版信息
Ann Intern Med. 2020 Nov 3;173(9):W147-W148. doi: 10.7326/L20-1177. Epub 2020 Sep 22.
Abstract
摘要
相似文献
1
Update Alert 4: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.最新警报4：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对新型冠状病毒感染的风险及影响
Ann Intern Med. 2020 Nov 3;173(9):W147-W148. doi: 10.7326/L20-1177. Epub 2020 Sep 22.
2
Update Alert 2: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.最新警报2：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的风险及影响
Ann Intern Med. 2020 Sep 1;173(5):W87. doi: 10.7326/L20-0969. Epub 2020 Jul 23.
3
Update Alert 3: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.更新警报3：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的风险及影响
Ann Intern Med. 2020 Oct 6;173(7):130-131. doi: 10.7326/L20-1068. Epub 2020 Aug 26.
4
Update Alert: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.最新警报：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的风险及影响
Ann Intern Med. 2020 Aug 4;173(3):W66. doi: 10.7326/L20-0887. Epub 2020 Jun 25.
5
Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.假说：血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂可能会增加 COVID-19 重症风险。
J Travel Med. 2020 May 18;27(3). doi: 10.1093/jtm/taaa041.
6
Update Alert 5: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.最新警报5：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对新型冠状病毒感染的风险及影响
Ann Intern Med. 2020 Dec 15;173(12):167-168. doi: 10.7326/L20-1293. Epub 2020 Oct 27.
7
Update Alert 6: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.更新警报6：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的风险及影响
Ann Intern Med. 2021 Jan;174(1):W17. doi: 10.7326/L20-1355. Epub 2020 Dec 1.
8
Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality.血管紧张素转换酶（ACE）抑制剂与血管紧张素II受体阻滞剂对2019冠状病毒病死亡风险的比较影响
Hypertension. 2020 Aug;76(2):e15-e17. doi: 10.1161/HYPERTENSIONAHA.120.15622. Epub 2020 Jun 3.
9
A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19.肾素-血管紧张素-醛固酮系统抑制剂与新型冠状病毒肺炎关系的Meta分析
Am J Cardiol. 2020 Sep 1;130:159-161. doi: 10.1016/j.amjcard.2020.05.038. Epub 2020 Jun 2.
10
COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?新型冠状病毒肺炎与血管紧张素转换酶抑制剂及血管紧张素受体阻滞剂：证据是什么？
JAMA. 2020 May 12;323(18):1769-1770. doi: 10.1001/jama.2020.4812.
引用本文的文献
1
Past, present and future of living systematic review: a bibliometrics analysis.生命系统综述的过去、现在和未来：文献计量学分析。
BMJ Glob Health. 2022 Oct;7(10). doi: 10.1136/bmjgh-2022-009378.
2
Update of the recommendations of the Sociedade Portuguesa de Cuidados Intensivos and the Infection and Sepsis Group for the approach to COVID-19 in Intensive Care Medicine.葡萄牙危重病医学会和感染与脓毒症组更新了对重症监护医学中 COVID-19 的处理建议。
Rev Bras Ter Intensiva. 2021 Oct-Dec;33(4):487-536. doi: 10.5935/0103-507X.0103-507X-rbti-20210080. Epub 2022 Jan 24.
3
Exploring Drugs and Vaccines Associated with Altered Risks and Severity of COVID-19: A UK Biobank Cohort Study of All ATC Level-4 Drug Categories Reveals Repositioning Opportunities.探索与新冠病毒疾病（COVID-19）风险和严重程度改变相关的药物和疫苗：一项针对英国生物银行所有解剖学治疗学化学（ATC）4级药物类别的队列研究揭示了重新定位的机会。
Pharmaceutics. 2021 Sep 18;13(9):1514. doi: 10.3390/pharmaceutics13091514.
本文引用的文献
1
Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China.中国武汉合并高血压的 COVID-19 感染患者的血压控制与不良结局。
Hypertens Res. 2020 Nov;43(11):1267-1276. doi: 10.1038/s41440-020-00541-w. Epub 2020 Aug 27.
2
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.肾素-血管紧张素-醛固酮系统抑制剂与 COVID-19 住院患者死亡风险：意大利 43000 例患者的回顾性队列研究。
Drug Saf. 2020 Dec;43(12):1297-1308. doi: 10.1007/s40264-020-00994-5.
3
Association between renin-angiotensin-aldosterone system inhibitor treatment, neutrophil-lymphocyte ratio, D-Dimer and clinical severity of COVID-19 in hospitalized patients: a multicenter, observational study.住院 COVID-19 患者中肾素-血管紧张素-醛固酮系统抑制剂治疗、中性粒细胞-淋巴细胞比值、D-二聚体与临床严重程度的关系：一项多中心观察性研究。
J Hum Hypertens. 2021 Jul;35(7):588-597. doi: 10.1038/s41371-020-00405-3. Epub 2020 Aug 24.
4
[Effects of angiotensin converting enzyme inhibitor/angiotensin receptor blocker on clinical characteristics of coronavirus disease 2019 patients with hypertension].血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂对2019冠状病毒病合并高血压患者临床特征的影响
Zhonghua Nei Ke Za Zhi. 2020 Sep 1;59(9):689-694. doi: 10.3760/cma.j.cn112138-20200229-00155.
5
Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications.新型冠状病毒肺炎患者的心衰：患病率、发病率和预后意义。
Eur J Heart Fail. 2020 Dec;22(12):2205-2215. doi: 10.1002/ejhf.1990. Epub 2020 Oct 7.
6
Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients.血管紧张素转化酶抑制剂/血管紧张素Ⅱ受体拮抗剂治疗新型冠状病毒肺炎有效性的系统评价和 Meta 分析：包含 28872 例患者的研究。
Curr Atheroscler Rep. 2020 Aug 24;22(10):61. doi: 10.1007/s11883-020-00880-6.
7
Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study.日本神奈川县肾素-血管紧张素系统抑制剂与 2019 年冠状病毒病严重程度的关系：一项回顾性队列研究。
Hypertens Res. 2020 Nov;43(11):1257-1266. doi: 10.1038/s41440-020-00535-8. Epub 2020 Aug 21.
8
Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use Among Outpatients Diagnosed With COVID-19.COVID-19 门诊患者中血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的使用情况。
Am J Cardiol. 2020 Oct 1;132:150-157. doi: 10.1016/j.amjcard.2020.07.007. Epub 2020 Jul 12.
9
Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19.血管紧张素转化酶抑制剂/血管紧张素Ⅱ受体拮抗剂与 COVID-19 合并高血压患者的死亡率降低相关。
Scott Med J. 2020 Nov;65(4):123-126. doi: 10.1177/0036933020949219. Epub 2020 Aug 17.
10
In-hospital use of ACEI/ARB is associated with lower risk of mortality and critic illness in COVID-19 patients with hypertension.在患有高血压的COVID-19患者中，住院期间使用血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂与较低的死亡率和危重症风险相关。
J Infect. 2020 Nov;81(5):816-846. doi: 10.1016/j.jinf.2020.08.014. Epub 2020 Aug 12.
Zotero 插件